Stephen Schmidt, MD
Family Medicine · Evans, GANPI 1790784593
Payments from drug & device makers
Across 381 payments — averaging $14.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$1K
- Abbott$405
- Amgen$315
- Johnson & Johnson$282
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$227
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,392100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 102 | $1,401 |
| AbbVie(2 entities) | 93 | $1,024 |
| Abbott | 23 | $405 |
| Amgen | 20 | $315 |
| Johnson & Johnson | 20 | $282 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $227 |
| Pfizer | 11 | $203 |
| Bayer | 10 | $167 |
| Lilly USA, LLC | 9 | $156 |
| GSK | 10 | $142 |
| AstraZeneca | 8 | $122 |
| Otsuka America Pharmaceutical, Inc. | 5 | $113 |
| Novartis | 6 | $110 |
| Astellas Pharma US Inc | 5 | $78 |
| Corcept Therapeutics | 4 | $70 |
| E.r. Squibb & Sons, L.L.C. | 5 | $61 |
| Dexcom, Inc. | 4 | $53 |
| Boehringer Ingelheim | 4 | $52 |
| Amarin Pharma, Inc. | 3 | $50 |
| Merck | 3 | $37 |
| Corium, LLC | 2 | $35 |
| Antares Pharma, Inc. | 2 | $30 |
| Globus Medical | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $26 |
| Echosens North America, Inc. | 1 | $25 |
| Neos Therapeutics, LP | 2 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 2 | $21 |
| Mylan Specialty L.p. | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Stryker | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Boston Scientific | 1 | $13 |
| Exact Sciences | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $12 |
How this compares
$5,392 in reported general payments places this provider in the 85th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 84 | $108,420 |
| MounjaroTirzepatide | 72 | $74,545 |
| EliquisApixaban | 73 | $71,948 |
| OzempicSemaglutide | 23 | $35,341 |
| XareltoRivaroxaban | 22 | $21,280 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 32 | $18,669 |
| RybelsusSemaglutide | 12 | $16,859 |
| MyrbetriqMirabegron | 26 | $13,984 |
| SynthroidLevothyroxine Sodium | 94 | $8,228 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 35 | $7,733 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $6,609 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $5,876 |
| Colesevelam Hcl | 11 | $5,811 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 36 | $4,247 |
| Fluticasone-Salmeterol HfaFluticasone Propion/Salmeterol | 11 | $3,859 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $52 | $108,42084 claims |
| Lilly USA, LLCMounjaro | $156 | $74,54572 claims |
| PfizerEliquis | $203 | $71,94873 claims |
| Novo NordiskOzempic, Rybelsus, Levemir | $1,401 | $53,41446 claims |
| GSKAnoro Ellipta, Shingrix, Breo Ellipta | $142 | $33,01078 claims |
| Johnson & JohnsonXarelto | $282 | $21,28022 claims |
| Astellas Pharma US IncMyrbetriq | $78 | $13,98426 claims |
| AbbVieSynthroid | $1,024 | $8,22894 claims |
| AstraZenecaSymbicort | $122 | $5,87617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Evans
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.